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Abstract
Background: The beta-1 adrenergic receptor (b1AR) plays a fundamental role in the regulation of cardiovascular
functions. It carries a nonsynonymous single nucleotide polymorphism in its carboxyl terminal tail (Arg389Gly),
which has been shown to associate with various echocardiographic parameters linked to left ventricular
hypertrophy (LVH). Diabetes mellitus (DM), on the other hand, represents a risk factor for LVH. We investigated the
possible association between the Arg389Gly polymorphism and LVH among non-diabetic and diabetic acute
myocardial infarction (AMI) survivors.
Methods: The study population consisted of 452 AMI survivors, 20.6% of whom had diagnosed DM. Left
ventricular parameters were measured with two-dimensional guided M-mode echocardiography 2-7 days after AMI,
and the Arg389Gly polymorphism was determined using a polymerase chain reaction-restriction fragment length
polymorphism assay.
Results: The Arg389 homozygotes in the whole study population had a significantly increased left ventricular
mass index (LVMI) when compared to the Gly389 carriers (either Gly389 homozygotes or Arg389/Gly389
heterozygotes) [62.7 vs. 58.4, respectively (p = 0.023)]. In particular, the Arg389 homozygotes displayed thicker
diastolic interventricular septal (IVSd) measures when compared to the Gly389 carriers [13.2 vs. 12.3 mm,
respectively (p = 0.004)]. When the euglycemic and diabetic patients were analyzed separately, the latter had
significantly increased LVMI and diastolic left ventricular posterior wall (LVPWd) values compared to the
euglycemic patients [LVMI = 69.1 vs. 58.8 (p = 0.001) and LVPWd = 14.2 vs. 12.3 mm (p < 0.001), respectively].
Furthermore, among the euglycemic patients, the Arg389 homozygotes displayed increased LVMI and IVSd
values compared to the Gly389 carriers [LVMI = 60.6 vs. 56.3, respectively (p = 0.028) and IVSd = 13.1 vs.
12.0 mm, respectively (p = 0.001)]. There was no difference in the LVMI and IVSd values between the diabetic
Arg389 homozygotes and Gly389 carriers.
Conclusions: The data suggest an association between the b1AR Arg389Gly polymorphism and LVH, particularly
the septal hypertrophy. The Arg389 variant appears to confer a higher risk of developing LVH than the
corresponding Gly389 variant among patients who have suffered AMI. This association cannot be considered to be
universal, however, since it does not appear to exist among diabetic AMI survivors.
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Cardiac left ventricular hypertrophy (LVH) is an impor-
tant risk factor for an adverse outcome in patients both
with or without coronary artery disease [1]. Further-
more, LVH represents an independent risk factor for
sudden cardiac death, congestive heart failure, coronary
heart disease and stroke, and it has been associated with
diabetes mellitus (DM) and glucose intolerance in sev-
eral epidemiological investigations [2-6]. On the other
hand, LVH can also be explained by genetic factors
[7-9] and its heritability has been estimated to be 0.17-
0.69 [10-12].
The beta-1 adrenergic receptor (b1AR) has been con-
sidered to represent a potential candidate gene for
LVH [12-15]. This G protein-coupled receptor is the
predominant beta adrenergic receptor in the heart
(~ 70% b1AR and 30% b2AR), maintaining cardiac con-
tractility in response to endogenous catecholamines
[16]. The b1AR gene is localized to 10q24-26 [17] and
was cloned in 1987 [18]. It encodes a 477-amino acid
membrane protein that carries two common nonsy-
nonymous single nucleotide polymorphisms, one in the
extracellular amino terminus (Ser49Gly) and another
in the proximal carboxyl terminus (Arg389Gly) [19].
The Arg389Gly polymorphic site lies within the puta-
tive Gs coupling domain of the receptor [20]. It has
thus been considered to have functional significance,
because the positively charged arginine residue differs
markedly from neutral glycine. Accordingly, the poly-
morphism has been shown to have an effect on signal-
ling properties of the receptor [21].
The aim of our study was to investigate the possible
association of the b1AR Arg389Gly polymorphism with
various variables, including cardiac left ventricular para-
meters, among acute myocardial infarction (AMI) survi-
vors in Northern Finland. We analyzed 452 patients,
20.6% of whom had diagnosed DM.
Methods
Patient population
The study population was recruited in 1996-2000. This
single-center, prospective study, the Multiple Risk Factor
Analysis Trial, was carried out at the Institute of Clinical
Medicine, Department of Internal Medicine, Division of
Cardiology, University of Oulu [22]. The aim of the
study was to determine the prognostic power of several
non-invasive risk markers of mortality among AMI sur-
vivors. A total of 452 consecutive series of patients who
had undergone AMI were investigated for the b1AR
Arg389Gly polymorphism. The patients were recruited
to participate in the study during the first week after the
AMI diagnosis, which was confirmed by using the con-
temporary guidelines at the beginning of the study. The
exclusion criteria and qualifying diagnosis have been
described previously [22].
Biometric and laboratory methods
Height and weight were measured for each patient by a
registered nurse. Body mass index (BMI) was obtained
from the ratio of weight (kg) to height squared (m
2).
Blood pressure was obtained in a supine position by a
registered nurse following a five minute resting period.
Blood samples were collected from the patients after an
overnight fast. The fasting glucose, total cholesterol,
HDL cholesterol, LDL cholesterol and triglyceride levels
were measured at the Institute of Diagnostics, Depart-
ment of Clinical Chemistry at Oulu University Hospital
using standard enzymatic methods.
Genotyping
The b1AR Arg389Gly polymorphism was determined by
using a polymerase chain reaction-restriction fragment
length polymorphism assay, a modified PCR-technique
described previously by Maqbool [19]. The restriction
endonuclease Bcg I used in the protocol was from New
England BioLabs (Beverly, MA, USA). The genotyping
was performed in 2009 using DNA samples which had
been stored at -20°C.
Echocardiography and variable calculation
Left ventricular parameters were measured within
2-7 days after AMI. Echocardiographic studies were per-
formed at the Institute of Clinical Medicine, Department
of Internal Medicine, Division of Cardiology at Oulu
University Hospital. Left ventricular internal dimension
(LVID), interventricular septal thickness (IVS) and left
ventricular posterior wall thickness (LVPW) were mea-
sured at end-diastole (d) and end-systole (s). The para-
meters were measured with two-dimensional guided
M-mode echocardiography following the American
Society of Cardiology/American Heart Association guide-
lines. Considering each parameter, three distinct mea-
surements were done and the averages were calculated.
Left ventricular mass (LVM) was calculated from
LVIDd, LVPWd and IVSd using the equation originally
described by Devereux and colleagues [23]. This method
gives values, which have been confirmed to be closely
related to the necropsy left ventricular weight. To obtain
LVMI, LVM was divided by height
2.7.
Data analysis
Statistical analyses were performed with SPSS 17.0/
PASW 18.0 software packages and where appropriate,
power calculations were performed with SamplePower
2.0. In the power calculations, alpha was set as 0.05.
The Hardy-Weinberg equilibrium was tested with the
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2 test. Student’s two-tailed t-test was used to compare
the quantitative parameters (expressed as means ± S.D)
between the groups, respectively. Categorical variables
were compared using the Χ
2 analysis. Analysis of covar-
iance (ANCOVA) was used for comparison of the echo-
cardiographic variables between the genotype groups
(expressed as means ± S.D). Using ANCOVA, the b1AR
Arg389Gly polymorphism was set as a fixed factor. Age
a n dB M Iw e r ea d d e da sc o - v a r i a b l e st oa d j u s tt h e
results. P < 0.05 was considered statistically significant.
Nominal p values are presented throughout, i.e. without
correction for multiple testing, as recommended by
Rothman [24].
Results
Characteristics of the AMI population
The main clinical and biochemical data of the study
population are shown in Table 1, in which the euglyce-
mic and diabetic patients have been analyzed separately.
As expected, the euglycemic and diabetic subgroups dif-
fered in many clinical aspects in addition to the history
of DM and fasting glucose. There were significantly
more women among the diabetic group, and the mean
age as well as BMI and fasting triglycerides were higher
as compared to the euglycemic group. Among the dia-
betic patients, the prevalence of congestive heart failure
was significantly greater, and therefore the use of diure-
tics and digoxin, and partly angiotensin-converting
enzyme inhibitors or sartans, was more frequent than
among the euglycemic individuals. Table 2 shows the
echocardiographic parameters, again analyzed separately
for the euglycemic and diabetic subgroups. As expected
[2-6], LVMI, and also LVPWd values were significantly
higher among the diabetic patients when compared to
the euglycemic individuals. Power calculations revealed
the power to detect differences between the euglycemic
and diabetic patients 100% for both LVMI and LVPWd.
Arg389Gly allele and genotype frequencies
The b1AR genotype at codon 389 was determined in
452 AMI survivors. The allele frequencies were 0.75 for
Arg389 and 0.25 for Gly389. These values were in
accordance with frequencies observed in other Cauca-
sian populations [25-27]. The frequencies of subjects
homozygous for the Arg389 or Gly389 alleles were 0.57
and 0.07. The genotype frequencies were also in line
with previous European studies [26,27]. The study popu-
lation was in Hardy-Weinberg equilibrium (Χ
2 = 0.817).




n = 359 (79.4%)
Diabetic patients
n = 93 (20.6%)
p value
Gender (male/female) 354/98 (78.3/21.7%) 289/70 (80.5/19.5%) 65/28 (69.9/30.1%) 0.027
Age (years) 60.8 ± 9.7 60.0 ± 9.5 63.8 ± 9.8 0.001
BMI 27.5 ± 3.8 27.3 ± 3.6 28.4 ± 4.4 0.014
Height (cm) 170.4 ± 8.4 170.6 ± 8.1 169.4 ± 9.4 NS
Weight (kg) 79.9 ± 13.2 79.6 ± 13.2 81.2 ± 13.2 NS
SBP (supine mmHg) 123.2 ± 19.1 122.7 ± 18.7 125.7 ± 20.7 NS
DBP (supine mmHg) 80.2 ± 10.9 80.5 ± 10.9 79.0 ± 11.2 NS
Congestive heart failure 45 (10.0%) 16 (4.5%) 29 (31.2%) < 0.001
Concomitant medications
Acetylsalicylic acid 392 (86.7%) 317 (88.3%) 75 (80.6%) NS
Beta blocker 440 (97.3%) 348 (96.9%) 92 (98.9%) NS
ACE inhibitor/sartan 179 (37.6%) 123 (34.3%) 47 (50.5%) 0.004
Diuretic 87 (19.2%) 50 (13.9%) 37 (39.8%) < 0.001
Calcium channel blocker 26 (5.8%) 21 (5.8%) 5 (5.4%) NS
Statin 176 (38.9%) 140 (39.0%) 36 (38.7%) NS
Warfarin 36 (8.0%) 28 (7.8%) 8 (8.6%) NS
Digoxin 19 (4.2%) 10 (2.8%) 9 (9.7%) 0.003
Amiodarone 6 (1.3%) 6 (1.7%) 0 (0%) NS
Fasting glucose (mmol/l) 6.4 ± 2.1 5.9 ± 1.4 8.3 ± 2.9 < 0.001
Total cholesterol (mmol/l) 5.4 ± 3.4 5.4 ± 3.7 5.3 ± 1.2 NS
HDL cholesterol (mmol/l) 1.1 ± 0.3 1.2 ± 0.3 1.1 ± 0.3 NS
LDL cholesterol (mmol/l) 3.4 ± 0.9 3.4 ± 0.9 3.4 ± 1.1 NS
Triglycerides (mmol/l) 1.6 ± 0.9 1.5 ± 0.9 2.0 ± 1.1 < 0.001
Student’s two-tailed t-test (quantitative variables) or Χ
2 analysis (categorical variables) was performed to compare the populations. BMI, body mass index; SBP,
systolic blood pressure; DBP, diastolic blood pressure; ACE, angiotensin-converting enzyme; NS, not significant. Data for continuous variables are presented as
mean ± S.D. Categorical variables are presented as number of subjects and as percentages (in parentheses).
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parameters
The echocardiographic parameters according to the
Arg389Gly polymorphism in the whole study population
are listed in Table 3. The Arg389 homozygotes were
found to have significantly increased mean LVMI when
compared to the Gly389 carriers (p = 0.023). In particu-
lar, the Arg389 homozygotes displayed thicker IVSd
measures when compared to the Gly389 carriers (p =
0.004). Power calculations indicated that the study sam-
ple had 67% power to detect differences in LVMI
between the Arg389 homozygotes and the Gly389 car-
riers. Furthermore, power calculations showed that the
required sample size for the achievement of power equal
to 80% would be 580 subjects. For IVSd, the power was
calculated to be 90%.
Table 4 shows the echocardiographic variables accord-
ing to the Arg389Gly polymorphism analyzed in the
euglycemic patients. The Arg389 homozygotes displayed
increased LVMI values compared to the Gly389 carriers
(p = 0.028). Again, particularly the IVSd values were
higher among the Arg389 homozygotes compared to the
Gly389 carriers (p = 0.001). The calculated powers were
62% for LVMI (required sample size for the achieve-
ment of 80% power would be again 580 subjects) and as
high as 100% for IVSd.
Table 5 shows that there wasn od i f f e r e n c ei nL V M I
and IVSd values between the diabetic Arg389 homozy-
gotes and Gly389 carriers. Ejection fraction (EF) was
slightly smaller among the Arg389 homozygotes when
compared to the Gly389 carriers (p = 0.049), but this
finding is most likely only random variation because of
the small sample size.
Discussion
The main finding of our study is the apparent associa-
tion of the b1AR Arg389 homozygotes with LVH among
euglycemic AMI survivors, and that this association
does not appear to exist among diabetic AMI survivors.
Analyzing 452 Finnish patients who had undergone
AMI, 79.4% of whom were euglycemic and 20.6% dia-
betic, we were able to show that the b1AR Arg389
homozygotes had significantly higher LVMI when com-
pared to the Gly389 carriers (either Gly389 homozygotes
or Arg/Gly389 heterozygotes). The same applied also to
IVSd, and this association was even stronger. Our result
Table 3 Echocardiographic variables in the whole study





n = 258 (57.1%)
Gly carriers
n = 194 (42.9%)
p value
LVMI 62.7 ± 19.1 58.4 ± 19.8 0.023
IVSd (mm) 13.2 ± 3.1 12.3 ± 2.7 0.004
LVIDd (mm) 49.8 ± 7.3 49.9 ± 6.7 NS
LVPWd (mm) 12.9 ± 3.6 12.5 ± 3.6 NS
EF 45.9 ± 8.7 46.2 ± 8.7 NS
ANCOVA was performed to compare the genotype groups. The polymorphism
was set as a fixed factor. Age and BMI were added as co-variables to adjust
the results. For abbreviations, see Table 2. Data are presented as mean ± S.D.
Table 4 Echocardiographic variables in the euglycemic
patients according to the b1AR Arg389 homozygotes and
Gly389 carriers
Euglycemic patients
n = 359 (79.4%)
Arg homozygotes
n = 203 (56.5%)
Gly carriers
n = 156 (43.5%)
p value
LVMI 60.6 ± 17.5 56.3 ± 19.2 0.028
IVSd (mm) 13.1 ± 3.0 12.0 ± 2.4 0.001
LVIDd (mm) 49.4 ± 7.3 49.9 ± 6.9 NS
LVPWd (mm) 12.6 ± 3.0 12.0 ± 2.8 NS
EF 46.6 ± 8.5 46.0 ± 8.4 NS
The analyses were performed and data are presented as described in Table 3.
For abbreviations, see Table 2.
Table 5 Echocardiographic variables in the diabetic
patients according to the b1AR Arg389 homozygotes and
Gly389 carriers
Diabetic patients
n = 93 (20.6%)
Arg homozygotes
n = 55 (59.1%)
Gly carriers
n = 38 (40.9%)
p value
LVMI 70.3 ± 22.8 67.2 ± 20.3 NS
IVSd (mm) 13.4 ± 3.3 13.5 ± 3.3 NS
LVIDd (mm) 51.1 ± 7.5 49.6 ± 6.5 NS
LVPWd (mm) 13.9 ± 5.2 14.6 ± 5.5 NS
EF 43.3 ± 9.0 46.9 ± 9.8 0.049
The analyses were performed and data are presented as described in Table 3.
For abbreviations, see Table 2.
Table 2 Echocardiographic variables of the euglycemic





n = 359 (79.4%)
Diabetic
patients





58.8 ± 18.3 69.1 ± 21.7 0.001
IVSd (mm) 12.8 ± 3.0 12.7 ± 2.8 13.4 ± 3.3 NS
LVIDd
(mm)
49.8 ± 7.1 49.6 ± 7.1 50.5 ± 7.1 NS
LVPWd
(mm)
12.7 ± 3.6 12.3 ± 2.9 14.2 ± 5.3 <
0.001
EF 46.0 ± 8.7 46.3 ± 8.4 44.8 ± 9.4 NS
ANCOVA was performed to compare the groups. The polymorphism was set
as a fixed factor. Age and BMI were added as co-variables to adjust the
results. LVMI, left ventricular mass index; IVSd, interventricular septal thickness
at end-diastole; LVIDd, left ventricular internal dimension at end-diastole;
LVPWd, left ventricular posterior wall thickness at end-diastole; EF, ejection
fraction. Data are presented as mean ± S.D.
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properties of the two receptor variants. The b1AR
Arg389 variant has been shown to display markedly
increased coupling to Gs and stimulation of adenylyl
cyclase in response to the agonist isoproterenol in vitro
as compared to the Gly389 receptor form [21]. Gly389
is thought to disrupt the predicted alpha-helical region
of the cytoplasmic carboxyl terminus of the receptor,
which may cause a less favorable receptor conformation
for coupling to Gs [28]. Thus, the b1AR Arg389 variant
can be considered as a “gain-of-function” receptor form.
It is well known that prolonged activation of the b1AR
leads to worsening of cardiac function. As a consequence,
b1AR expression is down-regulated and its coupling to
adenylyl cyclase is desensitized [29]. The Arg389Gly
polymorphism appears to modulate this pathological
situation: Mialet Perez et al., who used transgenic mice,
showed that the Arg389 variant is impaired in down-reg-
ulation, which most likely represents a protective event
in the failing myocardium. Furthermore, the young
Arg389 mice were found to have enhanced receptor
function and heart contractility compared to the Gly389
carriers, whereas the older Arg389 mice displayed a phe-
notypic switch with decreased signalling to adenylyl
cyclase and contractility compared to the corresponding
Gly389 mice [30]. In line with these in vivo studies, Rathz
et al.h a v es h o w nt h a tt h eb1AR Arg389 variant under-
goes less agonist-promoted desensitization in vitro com-
pared to its allelic counterpart [31]. Recently, Lewin and
colleagues have thrown light on the mechanism underly-
ing the b1AR-induced cardiac damage by showing that
inactivation of the cyclic AMP response element modula-
tor (CREM) rescued the b1AR-overexpressing mice from
cardiomyocyte hypertrophy, fibrosis, and left ventricular
dysfunction [32]. It would be interesting to know,
whether there is a difference in CREM expression and/or
function between individuals carrying either the Arg389
or Gly389 variant - a highly speculative possibility worth
investigating.
Our results support the notion that there is a direct
genetic impact of the b1AR Arg389 homozygosity on
the left ventricular structure. We cannot, however, rule
out the possibility that the observed increases in LVMI
a n dI V S da m o n gt h eb1AR Arg389 homozygotes were
related to hypertension because LVH partly represents
an adaptive response to hypertension [33]. In previous
studies it has been shown that the b1AR Arg389 homo-
zygotes have an increased risk to develop essential
hypertension among Scandinavians [34] and Chinese
[35]. We, nevertheless, did not detect higher blood pres-
sure values among the Arg389 homozygotes as com-
pared to the Gly389 carriers in our study population
(data not shown). This negative finding most likely
results from the anti-hypertensive medication of the
patients that took place after AMI and hospitalization
and/or from the relatively small sample size.
T oo u rk n o w l e d g e ,t h e r ea r ef o u rp r e v i o u ss t u d i e s
concerning the b1AR Arg389Gly polymorphism and left
ventricular structure. In accordance with our study, Fu
et al. described a significant association between the
b1AR Arg389 variant and LVH in Chinese hypertensive
individuals in two independent populations (n = 2417
and n = 327) [13]. In contrast, no relationship between
LVM and the b1AR Arg389Gly polymorphism was
found in a study population consisting of 110 healthy
Caucasian twin pairs (n = 220) [12]. In a third study by
Stanton and colleagues, the Gly389 homozygotes were
observed to have higher LVM when compared to the
Arg389 homozygotes among 249 Caucasian patients suf-
fering from renal failure [14]. This study consisted of a
very specific population: each individual had a proven
renal disease, 37% of whom were on renal replacement
therapy. This may explain the result that seems physio-
logically counter-intuitive. In the fourth study, Meyers et
al. who studied African American siblings suffering
from hypertension found no significant association
between the b1AR Arg389Gly polymorphism and LVMI
but reported that the Gly389 allele was significantly
associated with a higher mean relative wall thickness
compared to the Arg389 form [15]. This association was
not replicated in another study group consisting of a
Hispanic cohort. It is important to note that the Gly389
allele is more frequent in black populations [15,25],
which may explain the divergent findings.
When we analyzed the euglycemic and diabetic
patients of our study group separately, we did not find
any association between the b1AR Arg389Gly poly-
morphism and LVH among the diabetic patients. The
negative result can be considered to arise from an inde-
pendent association between DM and LVH [2-6], which
is presumably stronger than the association of the b1AR
Arg389Gly polymorphism with LVH. Therefore the
assumed stronger effect of DM can be expected to mask
the weaker effect of the polymorphism on the left ven-
tricular structure. Interestingly, the association between
DM and LVH seems to be stronger in women than in
men [2,5,6]. In our study population the proportion of
women was significantly higher among the diabetic sub-
group as compared to the non-diabetics one (30.1/
19.5%), supporting the hypothesis of the aforementioned
“masking effect” of DM. Furthermore, the b1AR expres-
sion has been shown to be markedly decreased in the
hearts of diabetic patients (atrial appendages) [36],
which may also have had an impact on our results.
Limitations
Evaluating left ventricular parameters from post-AMI
patients with two-dimensional guided M-mode
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happens to be in the area where the measures are being
taken from. Determining the EF with the M-mode
device has also limitations, because the systolic function
is measured only from a single point of the left ventricle.
Furthermore, in our study, echocardiography was per-
formed within one week after AMI, and consequently
hyperaemia may have contributed to the measurements
in addition to the left ventricular dysfunction and remo-
deling. Additionally, the amount of diabetic patients was
rather small in our study sample, which causes certain
limitations to the statistic analyses.
Conclusions
As a conclusion, we show here that LVMI and IVSd
values are significantly higher among AMI survivors
who are homozygous for the b1AR Arg389 variant com-
pared to the AMI patients carrying either one or two
copies of the Gly389 allelic form of the b1AR. The b1AR
Arg389 variant thus seems to confer higher risk of
developing LVH. In addition, we show that the afore-
mentioned association is not universal, since it does not
exist among diabetic AMI survivors. We hypothesize
that this negative finding is caused by the strong asso-
ciation between DM and LVH, which may mask the
presumably weaker effect of the b1AR Arg389 variant
on the left ventricular structure.
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